Stockreport

Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer’s Disease

Cortexyme, Inc.  (CRTX) 
PDF – In a Phase 1b trial, COR388 reduced levels of fragmented ApoE protein in cerebrospinal fluid of subjects with Alzheimer’s ––The drug’s target, the gingipains from P. g [Read more]